The upregulation of CD44 in NSCLC has played a crucial role in developing the development of nanocarriers, offering a focused strategy for drug administration that shows the potential to surpass the constraints of traditional therapies. The gene discussed is CD44; the disease is non-small cell lung carcinoma.